Search

Home > Cell & Gene: The Podcast > Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon
Podcast: Cell & Gene: The Podcast
Episode:

Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon
Category: Science & Medicine
Duration: 00:40:51
Publish Date: 2023-03-30 08:00:00
Description:

In December 2022, Atara Biotherapeutics’ Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV+ PTLD. The ground-breaking approval represents the first approval of an allogeneic T-cell immunotherapy ever, globally. Atara Bio's CEO, Pascal Touchon, talks to Cell & Gene: The Podcast's Erin Harris about the biopharma's path to regulatory approval, commercialization plans for Ebvallo, an in-depth look at EBV+ PTLD, the connection between EBV and serious diseases like multiple sclerosis (MS), and much more.
Total Play: 0